Реферат: Н. В. Матаниной, А. Р. Рейзис «Урсодезоксихолевая кислота и ее применение при вирусных гепатитах у взрослых и детей»


Список литературы к статье Н.В. Матаниной, А.Р. Рейзис
«Урсодезоксихолевая кислота и ее применение при вирусных гепатитах у взрослых и детей»

(Опубликована в журнале «Клинические перспективы гастроэнтерологии, гепатологии, колопроктологии», 2005 г., № 6, с. 11-15)


1. Shoda M. Uber die Ursodeoxycholsaure aus Barengallen und ihre physiologische Wirkung. J Biochem 1927:7;502-10.

2. Iwasaki T. Uber die Konstitution der Ursodeoxycholsaure. Z Physiol Chemm 1936;244:181-93.

3. Merhjian H.S., Phillips S.F., Hofman A.F. Colonic absorption of unconjugated bile acids: perfusion studies in man. Dig Dis Sci 1979;24:545-50.

4. Fedorowski T.L, Sale G, Callalilo A, Tint GS, Mosbach eh, Hall JC. Metabolism of ursodeoxycholic acid in man. J Gastroenterology, 1977;73:1131-7.

5. Mijayi K., Ariyama T., Ito M. et al. The effect of ursodeoxycholic acid on liver functions in patients with chronic liver disease: a double blind study in one institution and the effect on hepatic blood flow. Rinshoto Kenkyu, 1976;53:1395-403.

6. Yamanaka M., Oto M., Obata H. et al. The examenation of the therapeutic efficacy of UDCA on chronic hepatitis.A double blind study. Shindan to Chiryo 1976;64:2150-7.

7. Makino I., Shinozaki K., Yoshinok., Nakagawa S. Dissolution of cholesterol gallstones by UDCA. Jpn JGastroenterology 1975;72;690-702.

8. Leuschner U. et al. Gallstone dissolution in patients with chronic active hepatitis. Gastroenterology. 1981.Vol.80. P.1208.

9. Leuschner U. et al. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. Dig Dis Sci/1985. Vol.-30.P-642-649.

10. Crosignani A., Battezzati P.M., Setchell K.D.R et al. Effects of UDCA in serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose response study. J Hepatology 1991, 13:339.

11. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей. М, 2002.С.31, 254.

12. Leuschner U. UDCA influences immune parameters in patients with primary biliary cirrhosis Hepatology-1990.Vol.12.p.957.

13. Leuschner U. UDCA therapy in primary biliary cirrhosis. X11 International Bile Acid Meeting: Falk Symposium №68.Basel 1992.P.46-47.

14. Kitani K. UDCA of cholestatic diseases (Letter to the Editor) Lancet 11(8601) 1988;49.

15. Лазебник Л.Б., Ильченко Л.Ю., Голованова Е.В. Урсодеоксихолевая кислота. К 100-летию обнаружения. Ж. Консилиум Медикум. №6, т.4.М, 2002.

16. Fromm H, Sarva R.P, Bazzoli F. Formation of UDCA from chenodeoxycholic acid in the human colon: studies of the role of 7-ketolithocholic acid as an intermediate. J Lipid Res 1983;24:841-53.

17. Roda E., MazellaG., Bazzoli F. et al Effect of UDCA administration on biliary lipid secretion in primary biliary cirrhosis. Dig Dis Sci1989;34:528-88.

18. Kurtz W. Therapeutic effects of UDCA on the and gastrointestinal tract. Freiburg, 1992.P.41.

19. Sauerbruch T., Paumgartner G. Therapy der cholelitiasis. Internist.-1986-n.27.S.64.

20. Stiel A., Walker S., Stiel L. et al. Effect of UDCA on liver and bile duct disease in primary sclerosing cholangitidis. A 3-year pilot study with a placebo- controlled study period. J Hepatology 1994;20:57-64.

21. Tazuma S., Kajijama G., Mizuno T., Yamashita G. A combinaton therapy with simvastatin and UDCA is more effective for cholesterol gallstone dissolution that is UDCA monotherapy. J of Clinical Gastroenterology. 26(4) 1998, 287-291.

22. Setchell K.D., Balistreri W.F, Lin Q. et al. Metabolism of UDCA in normal subjects and in patients with cholestatic liver disease: biotransformation by conyugation and urinary excretion. XII International Bile Acid Meeting: Falk Symposium 68, Basel, 1992, P.37.

23. Nakayma F., Miyazaki K, Koga A. Effect of chenodeoxycholic and UDCA on isolated human hepatocytes. J Gastroenterology 78 (part 2) 1980, 1228.

24. Hofman A.F. Bile acid secretion, bile flow and biliary lipid secretion in humans. J Hepatology, 1990; 12;P.17.

25. Meier P.J. The bile salt secretory polarity of hepatocytes. J Hepatology, 1989;9;124 P..

26. Loria P., Carulli N., Medici G. et al. Determinants of bile secretion: effect of bile salt strukture on bile flow and biliary cation secretion. J Gastroenterology, 1989;96: 1142.

27. Stiehl A., Raedsch R., Rudolph G. Acute effects of UDCA and henodeoxycholate acid on the small intestinal absorbtion of bile acids. J Gastroenterology, 1990;98:424.

28. Galle P.R., Theilmann L., Raedsch R. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. J Hepatology 1990;12:486-91.

29. Heuman D.M., Mills A.S., Mc Call J. et al. Conjugates of ursodeoxycholate protect against cholestasis and hepato-cellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. J Gastroenterology, 1991;100:203-11.

30. Parguet M., Metman E.U., Raisman A., Raumband J.C. et al. Bioavailability, gastrointestinal transit, solubilisation and faecal excretion of UDCA in man EUR. J Clin Invest 1985;15:171-8.

31. Rodda E., MazellaG., Bazzoli F. et al. Effect of UDCA administration on biliary lipid secretion in primary biliary cirrihosis. Dig Dis Sci 1989;34:528-88.

32. Leuschner U., Fischer H., Kurtz W. et al. UDCA in primary biliary cirrhosis: results of controled double blind trial. J Gastroenterology 1989; 97; 1268-74.

33. Hempeling W., Dilger K., Beuers U. Systematic review: udca-adverse effects and drug interactions. Aliment Pharmacol Ther 2003;18:963-972.

34. Tint G.S., Salen G., Colatillo A. et al. UDCA: a safe and effective agent for dissolving cholesterol gallstones. Ann Itern Med 1982:97:351-6.

35. Trauner M., Craziadei J.W Review article: mechanisms of action and therapeutic applications of UDCA in chronic liver diseases. Aliment Pharmacol Ther 1999;13:979-96.

36. Hofman A.F. Pharmacology of UDCA an enterohepatic drug. Scand J Gastroenterology Suppl. 1994:204:1-15.

37. Beuers U., Fischer S., Spengler U., Paumgartner G. Formation of iso-ursodeoxycholic acid in man. J Hepatol 1991:13:97-103.

38. Lazaridis K.N, Gores G.J, Linder K.D. UDCA mechanisms of action and clinical use in hepatobiliary disorders J Hepatol 2001;35:134-46.

39. Poupon R., Chretien Y., Poupon R.E, Ballet F., Calmus Y.D. Arnis F. Is ursodeoxycholic acid effective treament for primary biliary cirrosis? Lancent, 1987;1:834-6.

40. Nittono H., Tokita A., Hayashi M. et al. UDCA therapy in the treatment of biliary atresia J Biomed Pharmacother 1989; 43: 37-41.

41. Batta A.K, Arora R., Salen G., Tint G.S., Eskreis D., Katz A. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liguid chromatography-mass Spectrometry: effect of ursodeoxycholic acid treatment. J Lipid Res 1989:30:1953-62.

42. Chretien Y., Poupon R., Gherardi M.F. et al. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis:effect of ursodeoxycholic treatment Gut, 1989;30:1110-5.

43. Fischer M.M., Paradine M.E. Influence of UDCA on biochemical parameters in cholestatic disease. J Gastroenterology 1986;90-1725.

44. Bachrach W.H, Hofmann A.F. UDCA in the treatment of cholesterol cholelithiasis. Dig Dis Sci. 1982; 27:737-61.

45. De Caestrecker J.S., Jazrawi R.P., Petroni M.U. Ursodeoxycholic acid in chronic liver disease. Gut. 1991Vol.32-p.1061-1065.

46. Beuers U., Spengler U., Kruis W. Ursodeoxycholic acid for treatment of primary sclerosing cholangitidis: a placebo-controlled trial. J Hepatology; 1992:16:707.

47. Van Thiel D.N., Wright H.J., Gavaler J.S. UDCA therapy for primary sclerosing cholangitidis (PSC):preliminary report of a randomized controlled trial L Hepatol. 1992; 16:62a.

48. Lo S.K., Hermann R., Chapman R.W. et al. UDCA in primary sclerosing cholangitidis: a double-blind placebo controlled trial.: J Hepatology 1992; 17:92.

49. Stiehl A., Waker S., Stiehl L.et al. Effect of UDCA on liver and bile duct disease in primary sclerosing cholangitidis a 3-year pilot study with a placebo-controlled study period. J Hepatology, 1994;20:57.

50. Stiehl A. Bile acid therapy in primary sclerosing cholangitidis. Proc.Basel Liver Week, Oct.17/18, 1995, 52.

51. Chazouilleres O., Poupon R., Capron J.P.et al. UDCA for primary sclerosing cholangitidis. J Hepatol 1990;11:120-3.

52. Harnois D.M., Angulo P., Jorgensen R.A., La Russo N.F., Lindor K.D. High-dose UDCA as a therapy for patients for patients with primary sclerosing cholangitidis Am J Gastroenterology 2001; 96:1558-62.

53. Pares A., Caballeria L., Rodes J. Long-term effects of UDCA in primari biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatology, 2000;32:561-6.

54. Chan C.W., Gunsar F., Feudjo M., Rigamonti C., Vla Chogiannakos J., Carpert J.R., Burroughs A.K. Long-term UDCA therapy for primary biliary cirrhosis: a follow up to 12 years. Aliment Pharmacol Ther 2005;21:217-226.

55. Okolicsanyi L., Groppo M., Floreani A., Morselli-Labate A.M, Rusticali A.G., Battocchia , Colombo M. Treatmen of primary sclerosing cholangitidis with low-dose UDCA: results of retrospective Italian multicentre Survey J Digestive and Liver Disease 3595)2003, 325-331.

56. Ивашкин В.Т., Буеверов А.О. Лечение больных с первичным билиарным циррозом печени. Ж. Аутоиммунные заболевания печени в практике клинициста. М., 2001.

57. Маевская М.В. Алкогольная болезнь печени Ж. Консилиум Медикум, т.3 №6 2001.

58. Vendemiale G., Grattagliano J., Signorile A., Altomare E. Ethanol-unduced changes of intracellular thiol compartmentation and protein redox status in the rat liver: Effect of tauroursodeoxycholate J Hepatol 1998; 28; 46-53.

59. Plevris J.N., Hayes P.C., Bouchier JAD. UDCA in the treatment of alcoholic liver disease. Eur J Gastroenterology, Hepatology 1991:3:653-6..

60. Montet A.M., Oliva L., Beauge F., Montet J.C. Bile salts modulate chronis ethanol-unduced hepatotoxicity. J Alcohol Alcohol, 2002 Jan-Feb;37(1) 25-9.

61. Чубенко С.С., Мальцева Н.В., Чубенко Д.С., Гайдуков В.О. Эффективность лечения неалкогольного стеатогепатита. РТГК, прил. 24 материалы X Российской конференции Гепатология сегодня 28-30 марта 2005г г.Москва..

62. Bittner P. Pathologie des hepatobiliaren Systems bei Mucoviszidose und therapeutishe Ansatze In H.Lindenmann (Hrsg): CF-Symposium Giezen 1988: Fortschritte in Diagnostic und Therapie der Mucoviczidose, 105-113.

63. Colombo C., Gjunta A., Podda M., Crosignani A., Zimmer-nechemias L., Setchell KDR The effect of ursodeoxycholic acid on liver function and bile acid metabolism in patients with cystic fibrosis and liver disease. Hepatology 10(4) 1989, 726, a-632.

64. Капустина Т.Ю., Каширская Н.Ю., Неудахин Е.В, Капранов Н.И. Длительное применение урсодеоксихолевой кислоты при поражении печени у больных муковисцидозом. Росс. гастроэнтерол.журнал №2, 2000г, М..

65. Chevrel B. Acide ursodeoxycholigue, cirrhose biliare primitive, cholangite sclerosante primitive, et mucoviscidose. Med Chir Dig. 18(5), 285-289.

66. Lindbland A., Glaumann H., Houwen B. A two-year prospektive study of the effect of UDCA on urinari bile acid escretion and liver morvology in cystic fibrosis-associated liver disease. J Hepatology 1998;27 166-74.

67. Smith J.L., Liwindon P.J., Hoskins A.C., Pereira T.N. Endogenous UDCA and cholic acid in liver disease due to cystic fibrosis Hepatology 2004 Iun; 39(6), 1673-82.

68. Stefaniwskiy A.B., Tint G.S., Speck J., Saden G., Shefer S. UDCA treatmen of bile reflux gastritis. J Gastroenterology 1985 89;1000-1004.

69. Rosman A.S. Efficacy of UDCA in the treating bile reflux gastritis J Gastroenterology 1987; JAN.92(1):269.

70. Coste T, Bodin M, Dellatolas F Efficacy of UDCA in the treatment of duodenogastric reflux in the antrectomized patients J Gastroenterology Clin B IOL 1991; 15;(8-9) 656-7.French.

71. Scarpa P.J., Cappell M.S., Chen W.Y., Lao W. Treatment with UDCA of bile reflux gastritis after cholecystectomy. J Clin Gastroenterology 1991 Oct; 13(5):601-3.

72. Шептулин А.А. Новые возможности применения урсодеоксихолевой кислоты в гастроэнтерологии. Ж. Клиническая медицина, 1996г.

73. Поспелова Т.И., Лосева М.И., Агеева Т.А., Маслова Л.М., Солдатова Г.С. Препарат Урсосан в лечении синдрома холестаза у больных гемобластозами в отдалённом периоде клинико- гематологической ремиссии Ж. Росс. Гастроэнтерологии, №1, 2000г.

74. Matsushita M., Nagasawa M., Sato Y., Soudo K., Kobayashi Y. Primary sclerosing cholangitidis associated with Limy Bile and Acute Pancreatitis J Pancreatology 2005 Jun. 28;(4-5):466-469.

75. Tsubakio K., Kiriyama K., Matsushima N., Taniguchi M., Shizusawa T., Katon T. et al. Autoimmune pancreatitis successfully treated with UDCA. Intem/Med.2002.Dec. 41(12):1142-6.

76. Alenezi B., Lamoureux E., Alpert L., Szilagyi A. Effect of UDCA on granulomatous liver disease due to sarcoidosis. Dig D IS Sci 2005, Jan;50(1):196-200.

77. Calmus Y., Guechot J., Podevin P., Bonnefis M., Giboudeau J., Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleikin 1, production by monocytes. J Hepatology 1992, 16;719-23.

78. Awm van Millegen-de-Wit, Kuiper H., Camoglio L Ivan Bracht, Jones E.A., Tytgat G.N., SJN van Deventer Does UDCA mediate immunomodulatory and anti- inflamotory effects in patients with primary sclerosing cholangitidis? European J of Gastroenterology and hepatology 11(2)1999, 129-136.

79.Zukowski T.H., Jorgensen R.A., Dickson E.R., Linder K.D. Autoimmune conditions associated with primary biliary cirrhosis: Response to ursodeoxycholic acid therapy. American J of Gastroenterology 93(6) 1998, 958-961.

80. Czaja A.J., Carpenter H.A., Lindor K.D. UDCA as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial/ J Hepatology 30(6) 1999, 1381-1386.

81. Li CP., Tong MJ, Hwang S.J., Luo J.C., CO R.L., Tsay S.H., Chang FY, LEE SD.Autoimmune cholangitidis with features of autoimmune hepatitis.Successful treatment J of Gastroenterology and Hepatology15(1) 2000, 95-98.

82. Nittino H., Tokita A., Hayashi M. et al.UDCA therapy in the treatment of biliary atresia Biomed Pharmacother 1989:43:37-41.

83. Ullrich D., Roting D., Schrote W., Hanefed F., Bircher J. Treatment with UDCA renders children with biliary atresia suitable for liver transplantation Lancet, 1987;2:1324.

84. Pos E, Navarro S., Bru C., Gilabert R., Bianchi L., Buguera M. UDCA treatment of primary hepatolithiasis in CArolis syndrome.Lancet 1993; 342;404-6.

85. Balestreri W.F., Setchell K.D., Ryckman F.C., and the UDCA study Group. Bile acid therapy in pediatric liver disease. In: Paumgartner G., Stiehl A., Gerok W. eds:Bile Acids and the Hepatobiliary System. London: Kluwer Academic Publishers, 1993:271-82.

86. Maggiore G., de Giacomo C. Efficacy of UDCA in preventive cholestatic episodes in a patient with benign recurrent intrahepatitc cholestasis. J Hepatology 1992; 16:504.

87. Whitington P.F. Cholestasis associated with total parenteral nutrition in infants J Hepatology 1985;5:693-6.

88. Spagnulo M.N., Jorio R., Vegnente A., Guarino A. UDCA for the treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. J Gastroenterology 1996; 111:716-16.

89. Kurktschiev D., Temelrova-Kurktschiev T.H., OM K., Schentke K. Successful immunomodulating in AIDS patients with UDCA- a pilot study. Clin Exp Immunol 1999 JAN; 115(1) 144-6.

90. Castiella A., Jribarren J.A., Lopez P., Arrizobalaga J., Rodrigues F von Wichmann M.A., Arenas J.I. UDCA in the treatment of AIDS-associated cholangiopathy. Am J Med 1997, Aug; 103(2):170-1.

91. Katsinelos P., Vasiliadis I., Patakiouta F., Christodoulou K., Pilpilidis J., Eugenidis N. UDCA for the treatment of amoxycillin-clavulanate potassium (Augmentin ®-induced intra-hepatic cholestasis: report of two cases: European J Gastroenterology and Hepatology 12(3); 2000, 365-368.

92. Meng L.J., Reyes H., Axelson M., Palma J., Hernandez J., Ribalta J., Sjovall J. Progesterone metabolites and acids in serum of patients with intrahepatic cholestasis of pregnancy: Effect of ursodeoxycholic acid therapy Hepatology 26(6) 1997, 1573-1579.

93. Belliveau P.P., Nightingale C.H., Qunitiliani R., Maderazo E.C. Reduction in serum concentrations of ciprofloxacin with hepatobiliary disease Clin Infect Dis 1994:19:354-5.

94. Hayakawa T., Hachiya H., Katagiri K., Hochino M., Yoshika N., Kawanura Y., Takeshima A. et al. Effect of bile acids on cholestasis induced by 17-ethinil estrodiol ( in Iapan)Acta HEPATOL Ipn.28(10)1987, 1354-1360.

95. Koga Y. Anticholestatic and cytoprotective properties of UDCA- Studies in vivo and in vitro (in Iap) Acta Hepatol. Ipn.28 (2) 1987, 1597-1604.

96. Friman S., Svanik J. A possible role of UDCA in liver transplantation. Scand J Gastroenterol. 1994; 29(suppl);62-4.

97. Sharara A.J., Camargo C.A., Clavien P.A. UDCA prevents rejection in liver transplant recipient Gastroenterol, 1995; 108(suppl):1168 A.

98. Kallinowski B., Theilmann L., Zimmermann K., Gams E., Kommerell B., Stiehl A. Effective treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid. Transplantation 1991;51:1128-9.

99. Persson H., Friman S., Schersten T., Svanvik I., Kallberg I. Adjuvant treatment with UDCA reduces acute rejection after liver transplantation. Transplant Proc 1992; 24:389-90.

100. Pgeaux G.P, Blac P., Ferrigault PF. et al.Failure of UDCA to prevent acute cellular rejection after liver transplantation. J Hepatology 1995; 23:119-22.

101. Keiding S., Hockerstedt K., Bjoro K. et al. The nordic multicenter double-blind randomized controlled trial of prophylaction UDCA in liver transplant patients/ Transplantation 1997;63:1594-4.

102. Caroli-Bosc F.X., Iliadis A., Salmon L. et al. UDCA modulates cyclosporin A oral absorbtion in liver transplant recipients Fundam Clim Pharmocol 2000:14:601-9.

103. Cadranel J.F, Martino V.V., Dorent R., Bernard B., Hoang C., Myara A., Pauwels A., Ghoussoub II., Perrin M., Grippon P..et al. Effects of UDCA(Ursodiol) treatment on chronic viral hepatitis in heart transplant patients: Results of a prospective, double-blind, placebo-randomized study. J Transplantaton 75(7) 2003 977-982.

104. Earnest D.L., Holubec H., Wali R.K., Jolly C.S., Bissonette M., Bhattacha Lyya, Roy H., Khare S., Brasitus T.A. Chemopreventon of azoxymethane-induced colonic carcinogenesis by supplementals dietary UDCA. Cancer R ES 1994 Oct 1;54(19):5071-4.

105. Oyama K., Shiota G., Ito H., Murawaki Y., Kawasaki H. Reduction of hepatocarcinogenesis by UDCA in rats. J Carcinogenesis 2002, May;23(5):885-92.

106. Narisawa T., Fukaura Y., Takeba N., Nakai K., Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats. Japanese J of Cancer Research 93(2), 143-150.

107. Paumgartner G., Beuers U. UDCA in cholestatic liver disease: mechanisms of action and therapeutic use revisited. J Hepatology 36(3) 2002;525-531.

108. Kitani K. Hepataprotective effect of UDCA in experimental animals. Abstr. Falr Symposium No 53; J Int Lugano Symposium on biliary Physiology and Disease: Strategies for the Treatment of Hepatobiliary Diseses, Lugano, Iune 15-17, 1989, 14.

109. Attili A.F., Angelico M., Cantafora A., Alvaro D., Capocaccia L. Bile-acid-induced liver toxicyty: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 19, 1986, p.56-69.

110. Hofmann A.F., Barrett K.E., Ouist R.G. Mechanisms of action of UDCA in the treatment of chronic cholestatic hepatobiliary disease: experiments and speculations. Abstr. Falk Symposiun NO53;J Int Lugano Symposium, Iune 15-17, 1989, 17..

111. Kimura T., Shimamura M., Iamaguchi A., Katajama T., Kirita T., Tanaka. Solubilisation of cultured cell membrane by bile acids(in Iapan). Acta Hepatol Ipn 22(1) 1989, 1-7.

112. Mitsuyoshi H., Nakashima T., Sumura Y., YOH., Nakajima, Ishikawa H. UDCA protects hepatocytes against ixydative injure via induction of antioxidants. Biochemical and Biophysikal Research Communications 263(2) 1999, 537-542.

113. Schomerich J., Miyal K., Baumgartner U., Gerok W. UDCA prevents taorolitocholate induced cholestasis in rat liver. J Hepatol. 78 (suppl 1) 1988, A-147.

114. Guldutuna S., Kurtz W., Pelecanos C., Zimmer G., Leuschner U. Mechanismen von membransschadigung und membranscgutz durch Gallensauren In: W.Kurtz (Hrsg): Gallensauren und MagenDarmtract, Verlag Htgieneplant Gmbh, Oberusel, 1988, 19-29.

115. Dumont M., Erlinger S., Uchman S. Hypercholeresis induced by UDCA and 7-ketoliticholic acid in the rat: possible role of bicarbonate transport.J Gastroenterology 1980; 79:82-9.

116. Yochikawa M., Tsujii T., Matsumara K., Yamao J., Matsumura Y., Kubo R. et al. Immunomodulatory effects of UDCA on immune responses. J Hepatology, 1992, 16:358-64.

117. Jazrawi R.P., DE Caestecker J.S., Goggin P.M., Britten A.J., Joseph AEA, Maxwell I.D. et al. Kinetics of hepatic handling in cholestatic liver disease: effect of UDCA. J Gastroenterology 1993;106:134-42.

118. Beuers U., Spengler U., Zwiebel F.M., Paulezki J., Fischer S., Paumgartner G. Effect of UDCA on the major hydrophobic bile acids in health and in chronic cholestasis liver disease. J Hepatology 1992; 15:603-8.

119. Krahenbuhl S., Talos C., Fischer S., Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. J Hepatology 1993; 19:471-9.

120. Lim A.G., Ahmed U.A., Jazrawi R.P., Northfield T.C. Effects of bile acids on human hepatic mitochondria. Eur J Gastroenterol Hepatol 1994; 6:1157-63.

121. Heuman D. Hepatoprotective pripeties of UDCA. J Gastroenterol 1993;104:1865-70.

122. Guldutuna S., Zimmer G., Imhof M., Bhatti S., Tiangeng Y., Leuschner U. Molecular aspekts of membrane stabilisation by ursodeoxycholate. J Hepatology, 1993; 104:1736-44.

123. Gores G. Mechanisms of cell injuri and death in cholestasis and hepatoprotecton by UDCA.J Hepatol 2000; 32( suppl. 2):11-3.

124. Надинская М.Ю. Исследование применения урсодеоксихолевой кислоты в гепатологии с позиции медицины, основанной на научных доказательствах Ж.Консилиум медикум, том 5 №6, 2003.

125. Beuers U., Nathanson M.H., Bayer I.L. Effects of tauroursodeoxycholic acid on cytosolic Ca-signals in isolated rat hepatocytes. J Gastroenterology 1993; 104:604-12.

126. Rodrigues C.M.P., Fan G.S., Wong P.Y., Kren B.T., Steer C. UDCA may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxigen species production.J Molekular Meicine 4(3)1998, 165-178.

127. Rodrigues C.M.P., Fan G.S., Ma XM., Kren B.T., Steer C. A novel role for UDCA in inhibiting apoptosis by modulating mitochondrial membrane perturbation J of Clinical Investigation 101(12) 1998, 2790-2799.

128. Cheng Y., Tauschel H.D., Nilsson A., Duan rd, UDCA ivcreases the activities of alkaline sphingomyelinase and caspase03 in the rat colon. Scadinavian J of Gastroenterology 34(9) 1999, 915-920.

129. Kurowa T., Iwasaki T., Ktaoka Y., Iwata N., Seto I., Hamano T., Terado N., Kakishita E. Effect of UDCA on expressi on of Fas-ligand and tumor necrosis factor-alpha in the liver of mice with acute graft-versus host disease. Current Therapeutic Research(11) 2000;825-836.

130. Fiorucci S., Mencarelli A., Palazetti B., DelSoldato P., Morelli A., Ignarro L.I. An NO derivativ of UDCA protects against Fas-mediated liver injury by inhibiting caspase activity. Proceedings of the national Academia of Sciences of the USA 98(5) 2001, 2652-2657.

131. Kren B.T., Rodrigies C.M.P., Setchell K.D.R., Steer C.I. Modulation of steady-state messenger RNA levels in the regenerating rat liver with bile acid feedig. Liver Transplantation 7(4) 2001, 321-334.

132. Silva rfm. Rodrigues C.M.P., Brites D. Bilirubin-induced apoptosis in cultured rat neural cells is aggravated by chenodeoxycholic but prevented by UDCA. J of Hepatology34(3)2001, 402-408.

133. Azzoroli F., Mehalw, Soroka C.I, Wang L., Lee J., Crispe N., Boyer J.L. UDCA diminishes Fas-ligand induced-apoptosis in mouse hepatocytes J Hepatology 36(1)2002, 49-54..

134. Sola S., Brito M.A., Brites D., Moura J.I.G., Rodrigues C.M.P. Membrane structural changes support the involvement of mitochondrial in the bile salt-induced apoptosis of rat hepatocytes.Clinical Science 103(5)2002, 475-485.

135. Lapennna D., Ciofani G., Festi D., Neri M., Pierdomenico S.D., Giamberardino M.A., Cucurullo F. Antioxidant properties of UDCA . Biochemical Pharmacol 64(11) 2002, 1661-1667.

136. Leuschner et al.Cholestasis liver disease in adult. New aspects in hepatology and gastroenterology: Falk Symposium № 108. Tbilisi, 1998.P-39-41.

137. Hoffman A.F. Strategies vor the hepatobiliary Disease. Eds. G. Paumgartner et al. Dordrecht. 1990. P-13-33.

138. Trauner M., Graziadei I.W. Review article: mechanisms of UDCA action and therapeutic applications of UDCA in chronic liver diseases. Alimentary Pharmacology and therapeutics 13(8) 1999, 979-995.

139. De Caesteker J.S., Iazrawi R.P., Petroni M.U. et al. Ursodeoxycholic acid in chronic liver disease.Cut.1991.Vol.32.P-1061-1065.

140. Buzzeli G., Moscarella S., Focardi G. UDCA in the treatment of chronic active hepatitis.A controlled clinico-therapeutic study Minerva Med.1992;83:537-40.

141. Lu C.L., Chan C.Y., Hwang S.J., Lu R.H., Lee S.D. Efficacy of UDCA in the treatment of patients with hepatitis C. J Gastroenterol Hepatol. 1995 jul-aug;10(4)432-7.

142. Kadayifci A., Savas M.S., Arslan S., Gullu I.H. Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B. J Clin Gastroenterol 1997;24:125-6.

143. Кузнецов В.В. Лечение хронических гепатитов урсосаном.Terra Medica/-1997, №1.С.40-41.

144. Nakashima T., Yoh T., Sumida Y., Kakisaka .Y, Mitsuyoshi H. Differences in the efficacy of UDCA and bile acid metabolism between viral liver diseases and primary biliary cirrhosis.J Gastroenterol Hepatol.2001 May;16(5):541-7.

145. Fabris P., Tositti G., Mazzella G., Zanetti A.R., Nicolin r, Pellizzer G., Benedetti P. Effect of UDCA administration in patients with acute viral hepatitis: a pilot study. Aliment Pharmacol Ther 1999;13:1187-1193.

146. Galsky J., Bansky G., Holubova T., Konig G. Effect of ursodeoxycholic acid in acute viral hepatitis. J Clin Gastroenterol.1999;Apr;28(3):249-53.

147. Odeh M., Oliven A. Treatment of prolonged cholestasis of acute hepatitis B with UDCA.Hepatology Research 13(1)1998, p.37-41.

148. Турьянов М.Х, Алленов М.Н, Сапронов Г.В. и др. Использование урсосана в терапии острых вирусных гепатитах.Сборник тезисов V Российского съезда врачей-инфекционистов. М, 15-17декабря 1998.-С.48.

149. Турьянов М.Х., Федосеев М.А. Применение урсодеоксихолевой кислоты при вирусных гепатитах Росс.гастроэнтерол.журн.1999.М2.С.72-75.

150. Ивашкин В.Т. Комбинированное лечение хронического гепатита В Росс.журн.гастроэнтерологии, гепатологии, колонопроктологии.1998.Н5.С.57-60.

151. Михайлов М.И., Симененко Т.А., Максимов В.А. УДХК в лечении хронических гепатитов(моно-и комбинированная терапия с препаратами интерферона) Гепатология и гастроэнтерология. 1994, №2.с.16-26.

152. Delich P., HofmanC.M., Luketic V.A. Treatment of chronic hepatitis C(HCV) with ursodeoxycholic acid(UDCA) in patients who failed interferon therapy Gastroenterology 1995;108;1057A.

153. Tanaka K., Kondo M., Sakaguchi T., Saito S., Arata S., Ikeda M., Ktamura T., Morimoto M., Sekihara H. Efficasy of UDCA in combination with interferon-alpha in treating chronic hepatitis C:results of a long-term follow-up trial.

154. Lirussi F., Becarello A., Bortolato L., Morselli-Labate A.M., Crovatto M., Ceselli S., Santini G., Crepaldi G. Long-term treatment of chronic hepatitis C with UDCA: influence of HCV genotypes and severity of liver disease.J Liver 1999, Oct.19(5)381-388.

155. Younossi Z.M., Perillo R.P. The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.Semin Liver Dis.1999 suppl 1:95-102.

156. Yagura M., Murai S. et al. Parameters predicting response to UDCA in chronic hepatitis C.J Hepatology Research 14(1);1999;18-25.

157. Топорков А.С. Применение УДХК при хронических вирусных гепатитах Ж.Консилиум медикум, том6, №3, 2004г.

158. Abdelmalek M.F., Harrison M.E., Gross J.B. Jr Poterucha J.J., Gossard A.A., Spivey J.R., Rakela J., Lindor K.D. Treatment of chronic hepatitis C with interferon with or UDCA:a randomised prospective trial L Clin Gastroenterol.1998.Mar;26(2):130-4.

159. Boucher E. Interferon and UDCA combined therapy in the treatment of chronic hepatitis C:Resalts from a controlled randomized trial in 80patients J Hepatology-1995.Vol.21. №2, p.322-326.

160. Angelico M., Gandin C., Pescarmona E. et al. Recombinant interferon-alpha and UDCA versus interferon-a alone in the treatment of chronic hepatitis C:a randomized clinical trial with long-term follow-up. Am J Gastroenterology.1995Vol.90.P.2630269.

161. Fabbri C., Marchetto S., Pezzoli A., Accogli E., Azzaroli F., Jaboli M.F., Montagnani M., Festi D., Roda E., Mazzella G. Efficacy of udca in association with alpha-interferon for chronic hepatitis C in alpha-interferon nonresponder patients Eur.J of Gastroenterol. Hepatol.12(5) 2000, 511-515.

162. Poupon R.E., Bonnand A.M., Queneau P.E., Trepo C., Zarski J.P., Vetter D., Raabe J.J., Thieffin G. et al. Randomized trial of interferon –alpha plus UDCA versus interferon plus placebo in patients with chronic hepatits C resistant to interferon.

163. Boucher E., Guyader D., Jacguelinet S., Andre P., Mendler M.H., Tutlin B., Canva V., Nousbaum J.B. et al.Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis:controlled randomized trial in 203 patients J Dig Liver Dis.2000 Jan.-Feb.;32(1):29-33.

164. Pigozzi M.G., Sorbara R., Baisini O., L di Stefano, Reggiani A., Lorini G. et al. A controlled randomized trial of t-UDCA as adjuvant to interferon for treatment of chronic hepatitis C: An interferon sparing effect of t-UDCA Hepatology Research 23(4)2002, 227-236.

165. Лупашко Ю.А. Эффективность сочетанной терапии интерфероном и УДХК у больных хроническим вирусным гепатитом С РЖГГК №1. 2005.тезис 61.

166. Colombo C. Cholestatic liver disease in children.In Falk Symposium №75 Cholestatic liver disease:Kluwer Academic Press, London 1994, 154-163.

167. Balistreri W.F. Bile acid therapy in pediatric hepatobiliary disease the role of UDCA . J Pediatr Gastroenterol Nutr.1997, May, 24(50:573-89.

168. Poupon R., Poupon R.E. UDCA therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther.1995 Apr;66(1):1-15.

169. Lambreht W., Whitington P.F. Cholestatic liver diseases in children. Current Science for Hospital and Practice Cholestatic liver disease in children and adults , Hamburg , Januari 25-6, 1996, p.2-3.

170. Kocak N., Saltik I.N. The effect of UDCA in children with prolonged hepatitis A virus invection that may be a trigger factor for autoimmune hepatitis Amer.J of Gastroenterol. 96(2) 2001, 610-611.

171. Narkewicz M.R., Smith D., Gregory C., Lear J.L., Osberg I., Sokol R.J. Effect of UDCA therapy on hepatic function in children with intrahepatic cholestatic liver disease. J of Pediatric Gastroenterol and Nutrition 26(1)1998, 49-55.

172. Fujisawa, Kimura A., Ushijima K., Nakashima E., Inoue T., Yamashita Y., Kato H. Intestinal absorption of UDCA in children and adolescent with inflammatory bowel disease. J of Pediatric Gastroenterology and Nutrition 26(3)1998, 279-285.

173. Holmes-Morton D., Salen G., Batta A.K., Shefer S., Tint G.S., Belchis D., Shneider B., Puffenberger E., Bull .L, Knisely A.S. Abnormal hepatic sinusoidal bile acid transport in Amish kindred is not linked to Fic 1 and is improved by ursodiol. J Gastroenterol 119(1)2000, 188-195.

174. Vajro P., Franzece A., Valerio G., Iannucei M.P., Aragione N. Lack of efficacy of UDCA for the treatment of liver abnormalities in obese children. J of Pediatric 136(6) 2000, 739-743.

175. Gilder M.A., Gann M.E., Opekun A.R., Gleason W.A. Efficacy of UDCA in the treatment of primary sclerosing cholangitidis in children. J of Pediatric Gastroenterology and Nutrition 31(2) 2000, 136-141.

176. Ozturk Y., Soyal C., Lebe B. Drug reaction to UDCA:Lichenoid drug eruption in infant using UDCA for neonatal hepatitis /case report. J of Pediatr Gastroenterology and Nutrition 35(3) 2002, 384-386.

177. Howard P.J., Murphy G.M. Bile acid stress in the mother and baby unit. European J of Gastroenterology and Hepatology 15(3)2003, 317-321.

178. Chen W., Liu Y., Glund C. Bile acids for viral hepatitis , 2003. Cochrane Database Syst Rev 2003, (2):CD 003181.

179. George R., Stevens A., Berkenbosch I.W., Turpin I., Tobias I. UDCA in the treatment of cholestasis and hyperbilirubinemia in pediatric intensive care unit patients. J South Med 2002 Nov; 95(11):1276-9.

180. Rifain E.L., Gottrand F. Role of UDCA in pediatric cholestatic disease. Gastroenterol Clin Biol.2004 Oct; 28(10pf1): 852-9.

181. Kelly-Oxford D.A. Disease of the liver and biliary system in children. Blackwell Science. 1999, P.432.

182. Никитина Т.С., Дрондина А.Н., Рейзис А.Р., Ананьева Н.П., Стулов А.П., Загузова Л.И., Иванчатенко Г.И. Первый опыт применения препаратов урсодеоксихолевой кислоты( урсофальк) при вирусных гепатитах, протекающих с холестазом в кн: Гепатиты В, С и Д-проблемы изучения, диагностики, лечения и профилактики М, 1995г, с.87,.

183. Рейзис А.Р., Дрондина А.Н., Никитина Т.С., Ананьева Н.П., Стулов А.П., Загузова Л.И., Иванчатенко Г.Н. Препараты урсодеоксихолевой кислоты в терапии холестазов при вирусных гепатитах у детей. Ж. Эпидемиология и инфекционные болезни, 1997, 49-51.

184. Рейзис А.Р., Дрондина А.Н., Никитина Т.С., Ананьева Н.П., Стулов А.П., Загузова Л.И., Иванчатенко Г.Н. Урсодеоксихолевая кислота в лечении острых и хронических вирусных гепатитов у детей. РГЖ, 1999г, №.с.44-49.

185. Выставкина Г.В., Писарев А.Г., Учайкин В.Ф, Чаплыгина Г.В. Лечение Урсосаном холестаза при острых и хронических вирусных гепатитах у детей. Ж. Детские инфекии. 2002 №1.С. 40-42.

186. Молочкова О.В., Чередниченко Т.В, Гаспарян М.О, Чаплыгина Г.В. Течение гепатита С у детей. Ж. Детские инфекции. 2002г.№1.С.21-23.

187. Рейзис А.Р. Терапия и профилактика хронических гепатитов В и С у детей и подростков. Современные проблемы профилактической педиатрии. М.2003г. С.6-8.

188. Баранов А.А., Каганов Б.С., Учайкин В.Ф. и авторский коллектив Диагностика и лечение хронических вирусных гепатитов В, С, Д у детей. Пособие для врачей. М.2003г.

189. Рейзис А.Р., Нурмухаметова Е.А. Вирусные гепатиты у детей с онкогематологическими заболеваниями. Ж. Медицина для всех. №1 1996. С. 24-27.

190. Котович М.М. Роль этиотропной и патогенетической терапии в клинической и морфологической эволюции хронических гепатитов у детей. Автореф.дисс.докт.мед. наук, М, 2003.

191. Рейзис А.Р. Лечение хронического гепатита С у детей и подростков интерфероном L-2a. Вопросы современной педиатрии.2002.№1.Т.1С.17-21.

192. Гаспарян М.О., Чаплыгина Г.В., Гусева Н.А. Естественное течение и отдалённые исходы ХГ В у детей. Тезисы докладов Росс.научно-практич. Конференции.19-20 мая 2004г.М..

193. Рейзис А.Р., Дрондина А.Н., НикитинаТ.С. и др. Комплексная терапия хронического гепатита С у детей и подростков. Вопросы современной педиатрии том3, прилож.3, 2004г.с.80.

194. Jara P., Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in childhood :a consensus advice based on experience in European children. Pediatr.Gastroenterol. Nutr.1999.29(2)P.163-170.

195. Sokal E. Treatment of pediatric chronic hepatitis B-new millenium. EASL 2001.APR, 18-22.P.68-69.

196. Рейзис А.Р., Никитина Т.С., Дрондина А.С., Ананьева Н.П., Залуцкая А.Н., Загузова Л.И., Иванчатенко Г.И. Патогенетическая терапия вирусных гепатитов, протекающих на фоне соматической патологии у детей.. Росс.гастроэнтеролог.журн.№1, 2001, стр.83, томХ1V.

197. Рейзис А.Р., Никитина Т.С., Дрондина А.С. и др. УДХК как фоновая терапия заболеваний гепатобилиарной системы у детей и подростков. Сб.статей Новые возможности в лечении заболеваний печени. М, 2002 с.54.

198. Fitz I. Ursodeoxycholate increase cytosolic calcium concentration and activates chlor-anion currents in billiary cell line.Gastroenterology 1995;109:965-72.

199. Roberts L., R., Bronk S.F., Gores G. Effector proteases in bile salt-induced hepatocyte apoptosis.Bile acids in Hepatobiliary Diseases.1997, 265-271.

200. Guicciardi M.E, Gores G.I. Is ursodeoxycholic acids an antiapoptotic drug? Hepatology 1998;28:1721-3.

201. Nasir T., Arona H.S, Kaiser H.E. Apoptosis and pathogenesis of viral hepatitis C-an update in vivo.2002.Vol.14.p.297-300.

202. Kountouras I., Zaros C., Chatzopoulos D. Apoptosis in hepatitis C J Viral Hepat.2003, Sept.10(5);335-42.

203. Rodrigues C.M.P. UDCA modulates cell cycle proteins that control apoptosis of primary rat hepatocytes 40th Annual Meeting of the European Association for the Study of the liver, Apr. 13-17, 2005, Paris.

204. Рейзис А.Р., Шмаров Д.А. Апоптоз в патогенезе синдрома холестаза и возможности его коррекции. Материалы Х11 конгресса гастроэнтерологов Актуальные проблемы абдоминальной патологии, 8-10 дек. М, 2004.
еще рефераты
Еще работы по разное